Adma Biologics reported $64.2M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Adma Biologics USD 64.2M 12.21M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Takeda JPY 1.11T 85.29B Mar/2026